Deregulation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) intracellular signaling pathway is common in breast cancer (BC) and has been found to be potentially implicated in resistance to endocrine and anti-HER2 therapies. Targeting the PI3K/Akt/mTOR pathway may remove this inhibition and restore sensitivity to these compounds. Buparlisib (BKM120) is a potent oral pan-class I PI3K inhibitor that is being extensively evaluated in multiple tumor types.
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer
MILANI, Andrea;MARTINELLO, Rossella;AVERSA, Caterina;VALABREGA, Giorgio;
2015-01-01
Abstract
Deregulation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) intracellular signaling pathway is common in breast cancer (BC) and has been found to be potentially implicated in resistance to endocrine and anti-HER2 therapies. Targeting the PI3K/Akt/mTOR pathway may remove this inhibition and restore sensitivity to these compounds. Buparlisib (BKM120) is a potent oral pan-class I PI3K inhibitor that is being extensively evaluated in multiple tumor types.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Buparlisib an oral pan PI3K inhibitor for the treatment of breast cancer.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
689.75 kB
Formato
Adobe PDF
|
689.75 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
